MicroRNA‐941 Acts as a Novel Prognostic Predictor and Oncogenic Driver in Colorectal Cancer Authors: Hong Li, Yang Liu, Hua Chen, Jialin Li, Xinchun Li, Yanmin Chen Published: 2026 ABSTRACT ABSTRACTAimThis study aims to ascertain the expression status, clinical significance, and biological function of microRNA‐941 (miR‐941) in colorectal cancer (CRC). It elucidates the role of miR‐941 in tumor development and the underlying mechanism involving the transcriptional repressor GATA binding 1 (TRPS1).MethodsSerum samples were collected from 150 CRC patients and 150 healthy controls to examine the relative amounts of miR‐941. The diagnostic value of miR‐941 was evaluated by plotting receiver operating characteristic (ROC) curves. Kaplan–Meier and Cox regression analyses were employed to assess the prognostic implications of miR‐941. Functional experiments were conducted in CRC cell lines. The target gene of miR‐941 was identified and confirmed through bioinformatics analysis and a dual‐luciferase reporter assay.ResultsAn increased level of miR‐941 was found in CRC patients and cell lines (p < 0.001). The preliminary diagnostic performance showed an area under the ROC curve (AUC) of 0.882. Its high expression was tightly in relation to advanced tumor node metastasis stage, lymph node metastasis, and inferior overall survival, serving as an independent prognostic factor (HR = 2.217, p = 0.005). Functionally, inhibition of miR‐941 suppressed cellular behaviors and induced changes with ferroptosis phenotypes. Mechanistically, TRPS1 was predicted and verified to be a direct target of miR‐941 at both mRNA and protein levels. Moreover, knockdown of TRPS1 could reverse the tumor‐suppressive effects and ferroptosis‐related changes caused by miR‐941 inhibition.ConclusionOur results identify miR‐941 as a novel oncogenic driver in CRC through targeting of TRPS1, serving as a valuable prognostic indicator. Introduction Colorectal cancer (CRC) represents one of the most common malignant neoplasms of the digestive tract worldwide [1], with its incidence and mortality rates occupying leading positions all over the world, posing a persistent and severe threat to public health [2, 3]. In China, the prevalence of CRC has escalated rapidly, which is associated with several factors, including socioeconomic development, the acceleration of population aging, and the adoption of Western dietary patterns [4, 5]. Despite considerable progress in early diagnostic techniques and comprehensive treatment modalities over the past few decades [6, 7], a significant number of patients are still diagnosed at advanced stages due to metastasis and recurrence, resulting in inferior clinical outcomes [8, 9]. Consequently, investigating the molecular mechanisms underlying the initiation and progression of CRC, as well as identifying novel biomarkers for early diagnosis and prognosis assessment, has become a critical scientific question that requires urgent resolution in CRC research. Tumorigenesis is a multi‐step process that involves precise gene regulation [10, 11]. MicroRNAs (miRNAs), which are small non‐coding RNAs ranging from 19 to 25 nucleotides, serve as key post‐transcriptional modulators by binding to the 3′‐untranslated regions (UTRs) of target mRNAs, thereby mediating degradation or translational inhibition [12, 13, 14]. Their dysregulation is implicated in the hallmarks of cancer, with specific miRNAs functioning as either oncogenes or tumor suppressors [15, 16, 17]. Among the tumor‐associated miRNAs, microRNA‐941 (miR‐941) has garnered increasing attention from researchers. The literature demonstrates that miR‐941 exhibits significant tissue specificity in its expression patterns and functions. For instance, studies have reported its upregulation in lung adenocarcinoma tissues, where it promotes tumor cell growth by regulating specific signaling pathways [18]. Furthermore, miR‐941 influences the proliferative capacity of breast cancer cells [19] and has been identified as a potential diagnostic biomarker in laryngeal squamous cell carcinoma [20]. However, research on miR‐941 in CRC remains limited. The expression profile of miR‐941, its associations with patients' clinical outcomes, its biological roles, and the underlying mechanisms have not yet been systematically and clearly elucidated. Recent studies have demonstrated that ferroptosis plays a critical tumor‐suppressive role in various cancers, including CRC [21]. Transcriptional repressor GATA binding 1 (TRPS1), as a transcription factor, has been implicated in the regulation of genes involved in oxidative stress response and redox homeostasis; however, its direct role in ferroptosis has not been previously explored [22]. MiRNAs that target tumor suppressors often simultaneously regulate multiple cancer hallmarks, including cell death pathways [23]. Given the emerging role of ferroptosis in tumor suppression, we hypothesized that miR‐941 might protect CRC cells from ferroptosis‐related pathogenesis. In the present study, we aim to elucidate the clinical significance and biological functions of miR‐941 in CRC. We conducted an analysis of the expression levels of miR‐941, assessing its diagnostic and prognostic value using clinical samples. Furthermore, in vitro cell models were utilized to investigate the regulatory role of miR‐941 in the malignant phenotype of CRC cells. Additionally, through bioinformatics prediction and molecular biology experiments, we will identify the direct targets of miR‐941 and preliminarily elucidate its functional pathways. The objective of this research is to establish new theoretical foundations and identify potential targets for molecular subtyping, prognostic assessment, and targeted therapy in CRC. Methods and Materials Clinical Samples A total of 150 patients admitted to Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), with a histopathologically confirmed diagnosis of primary CRC, were selected for inclusion in the study. The inclusion criteria for patients were as follows: (1) Postoperative pathology confirmed CRC; (2) No prior anticancer treatments before admission; (3) Complete and traceable clinical records and follow‐up documentation; (4) Availability of preoperative serum samples for testing at admission. Exclusion criteria for patients included: (1) Concurrent primary malignancies in other organs or hematological disorders; (2) Severe underlying conditions such as significant cardiac, hepatic, or renal insufficiency; (3) Recent immunosuppressive therapy within the past week; (4) Pregnant or lactating female patients; (5) Severe autoimmune diseases or coagulation disorders. A total of 150 healthy volunteers who underwent physical examinations at the hospital during the same period were designated as the control group. This control group was matched to the patient group based on fundamental demographic characteristics, including age and gender, and was carefully screened to exclude individuals with malignant tumors, digestive system diseases, or systemic inflammatory diseases through comprehensive physical examinations. Clinical and pathological characteristics were systematically collected for all subjects, encompassing age, sex, tumor location, tumor size, tumor node metastasis (TNM) stage, differentiation, and lymph node metastasis (LNM). Following the postoperative period of CRC patients, a 5‐year overall survival follow‐up was conducted via telephone or WeChat to document patient survival status. Follow‐up visits were scheduled every 3 months during the first and second years, every 6 months during the third and fourth years, and annually during the fifth year. Overall survival was defined as the time interval from the date of surgical resection to death from any cause or the last follow‐up assessment. Serum samples were collected from all 300 study subjects (150 patients and 150 controls). For CRC patients, serum samples were collected preoperatively within 24 h before surgical resection. Postoperative samples were not collected in this study. To investigate the relationship between serum and tissue miR‐941 expression, 30 CRC patients were randomly selected from the 150‐patient cohort using a stratified sampling method: patients were ranked by serum miR‐941 levels from low to high and equally divided into three strata, and 10 patients were randomly selected from each stratum. For these 30 patients, paired tumor and adjacent normal tissue samples were collected intraoperatively. These tissue samples were also used to examine TRPS1 expression and to validate the miR‐941/TRPS1 correlation in tumor tissues. The study was conducted between February 2019 and February 2021. The study protocol was subjected to a rigorous review process by the Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City) ethics committee, which ultimately resulted in its formal approval (Approval Number 2026‐021‐01). All participants have signed written informed consent before sample enrollment. Serum levels of carcinoembryonic antigen (CEA) were quantified using an electrochemiluminescence immunoassay kit (Roche Diagnostics, Germany) in accordance with the manufacturer's instructions. Cell Culture and Transfection The human CRC cell lines (HCT116, SW620, LoVo, SW480) and normal human colorectal epithelial cell line (NCM460) were purchased from Shanghai GeneChem Co. Ltd. (Shanghai, China). All cell lines were authenticated by short tandem repeat (STR) profiling and tested negative for mycoplasma using MycoAlert Mycoplasma Detection Kit (Lonza, cat. No. LT07‐318). Cells were used within 10 passages after thawing. All cell lines were routinely cultured in DMEM medium, which was supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin. The cultures were maintained at 37°C in a humidified incubator containing 5% CO2. To investigate the function of miR‐941, HCT116 and SW620 were selected for the next experiments. The transfection process was executed by employing Lipofectamine 3000 (Thermo Fisher Scientific), in accordance with the stipulated protocol provided by the manufacturer. The following transfection groups were established: control, inhibitor negative control (inhibitor‐NC), miR‐941 inhibitor, TRPS1 siRNA (si‐TRPS1), and si‐NC, which were obtained from GeneChem (Shanghai, China). The miR‐941 inhibitor sequence was 5′‐GCACAUGUGCACACAGCCGGGUG‐3′. The NC‐inhibitor sequence was 5′‐UCACAACCUCCUAGAAAGAGUAGA‐3′. For TRPS1 knockdown, the sequences of si‐TRPS1 and si‐NC were UUAUCAGAAAUGUUAUCGCU and UUCUCCGAACGUGUCACGUTT. RNA Extraction and Quantitation Real‐Time Polymerase Chain Reaction Serum samples were collected preoperatively and processed within 2 h of collection, centrifuged at 3000g for 10 min at 4°C, and stored at −80°C until use. Repeated freeze–thaw cycles were avoided. Total RNAs were isolated from 200 μL serum using TRIzol LS Reagent (Thermo Fisher) and from cells with TRIzol Reagent (Invitrogen), respectively, in accordance with the manufacturer's protocol. For tissue samples, total RNA was extracted using TRIzol reagent (Thermo Fisher) following the directions provided by the manufacturer. To eliminate genomic DNA contamination, RNA samples were treated with DNase I (Thermo Fisher) according to the manufacturer's protocol. The assessment of RNA concentration and purity was conducted utilizing a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, USA). The A260/A280 ratio, a key indicator of biological samples, was measured within the specified range of 1.8–2.0, ensuring the accuracy and precision of the analysis. Primer sequences were as follows: miR‐941 forward: 5′‐GCACCCGGCTGTGT‐3′, miR‐941 reverse: 5′‐CTCAACTGGTGTCGTGGA‐3′; RNU6B forward: 5′‐TCGCTTCGGCAGCACATAT‐3′, reverse: 5′‐ATTTGCGTGTCATCCTTGC‐3′; TRPS1 forward: 5′‐ATGACACTCCTGTTGGGTACT‐3′, reverse: 5′‐CGTGCTGCTTGCCATAATGTT‐3′; GAPDH forward: 5′‐ACAACTTTGGTATCGTGGAAGG‐3′, reverse: 5′‐GCCATCACGCCACAGTTTC‐3′. For reverse transcription, 10 ng of total RNA was used with the PrimeScript RT Kit (Takara, Dalian, China) to synthesize cDNA. Subsequently, amplification was conducted on the QuantStudio 5 Real‐Time Fluorescent Quantitative PCR System (Applied Biosystems, USA) with the SYBR Green Premix Kit (Accurate Biology, China). Amplification efficiency was determined using standard curve analysis and ranged from 98% to 102% for each gene. Melting curve analysis confirmed single specific peaks for each amplicon, with no primer‐dimer or nonspecific amplification products. No‐template controls and no‐reverse‐transcription controls were included in each run to exclude contamination and genomic DNA amplification. RNU6B was used as the endogenous control for serum miRNA normalization, as previously validated for circulating miRNA studies [24, 25]. The stability of RNU6B was confirmed in our cohort: the coefficient of variation (CV) of RNU6B Ct values across all serum samples was 2.42%, and no significant difference in RNU6B Ct values was observed between the two groups (p = 0.82, Mann–Whitney U test). GAPDH was utilized as the internal reference gene for serum cell‐free mRNA normalization based on studies demonstrating its stability in circulating mRNA analyses [26, 27]. In the cohort, GAPDH Ct values showed no significant difference between healthy controls and CRC patients (p = 0.93), with its CV across all serum samples of 1.48%, supporting its suitability as a normalization control. In cells, RNU6B and GAPDH were also used as reference genes. The experimental design entailed three replicates for each sample, with the relative expressions of miRNA and mRNA determined utilizing 2−ΔΔCt method. Cell Proliferation Examination Cell proliferation capacity was assessed using a CCK‐8 assay kit. The transfection of cells was conducted in a 96‐well plate, with five replicate wells established for each group. Following 24, 48, and 72 h of transfection, 10 μL of CCK‐8 solution was added. Subsequently, the plates were incubated for 2 h. Absorbances at 450 nm were measured by means of a microplate reader. Transwell Assay For the migration assay, cells that had been transfected for 48 h were resuspended in a serum‐free medium. A total of 200 μL of this cell suspension was placed into the upper chamber of the Transwell, while the lower chamber was filled with 500 μL of complete medium containing 20% FBS to promote cell growth and migration. After a 24‐h incubation period, the cells remaining in the upper chamber were removed using a cotton swab, allowing for the evaluation of those cells that had migrated to the lower chamber. Following fixation with 4% paraformaldehyde and staining with 0.1% crystal violet, five fields of view were randomly selected and examined under an inverted microscope. For the invasion assay, the polycarbonate membrane in the Transwell upper chamber was pre‐coated with Matrigel matrix gel to simulate the extracellular matrix barrier. The remaining steps were performed as previously described. Cell Cycle Detection For cell cycle analysis, flow cytometry was performed. After collection, the cells were stained with a cell cycle detection kit (BD Biosciences) and analyzed on a FACS Aria III system (BD Biosciences). Data regarding the proportion of cells in the G0/G1, S, and G2/M phases were processed with Modfit software (USA). Ferroptosis‐Related Biomarker Assays To investigate cellular ferroptosis‐related levels, malondialdehyde (MDA) and glutathione (GSH) contents were measured using commercial kits (Nanjing Jiancheng Biology, China). The ROS assay was assessed using Reactive Oxygen Species Assay (C1300, APPLYGEN, Beijing, China), following the directions provided by the manufacturer. Dual‐Luciferase Reporter Assay A DNA fragment containing the transcriptional repressor GATA binding 1 (TRPS1) mRNA 3′‐UTR was synthesized and cloned into the pmiGLO reporter plasmid (Promega, USA) to create the wild‐type reporter plasmid (TRPS1‐wt). Concurrently, the predicted miR‐941 binding site underwent site‐directed mutagenesis to generate a mutant reporter plasmid (TRPS1‐mut). Human embryonic kidney cells HEK‐293T were seeded in 24‐well plates, and the transfection was performed using Lipofectamine 3000 reagent. Following a 48‐h transfection period, the cells were harvested and lysed using the Dual‐Luciferase Reporter Gene Assay System (Promega, USA). Western Blot Analysis For western blot analysis, total protein was extracted from HCT116 and SW620 cells using RIPA lysis buffer containing protease inhibitors. Protein concentrations were determined using the BCA assay. Equal amounts of protein were separated by 10% SDS‐PAGE and transferred to PVDF membranes. Membranes were blocked with 5% non‐fat milk and incubated overnight at 4°C with primary antibodies against TRPS1 (1:1000, Cell Signaling, #17936), glutathione peroxidase 4 (GPX4, 1:1000, Cell Signaling, #52455), solute carrier family 7 member 11 (SLC7A11, 1:1000, Cell signaling, #98051), and GAPDH (1:5000, Cell Signaling, #2118). Antibody specificity was validated by the manufacturer and confirmed by the presence of single bands at the expected molecular weights. After incubation with HRP‐conjugated secondary antibodies (Cell Signaling, #7074), protein bands were visualized using ECL detection reagent and quantified by densitometry using ImageJ software. Statistical Analysis All statistical analyses were performed using IBM SPSS Statistics version 26.0 and GraphPad Prism version 9.0 software. Quantitative data that met the assumptions of normal distribution were presented as mean ± standard deviation (SD). Intergroup comparisons were conducted using independent samples t‐tests. A one‐way analysis of variance (ANOVA) was employed to analyze multiple groups of quantitative data. Comparisons among groups for categorical data were carried out using Chi‐squared (χ 2) tests. The diagnostic performance of miR‐941 was evaluated by plotting the receiver operating characteristic (ROC) curve. Combined ROC analysis of miR‐941 and CEA was performed using binary logistic regression to generate predicted probabilities. For survival analysis, patients were dichotomized into high and low miR‐941 expression groups based on the mean expression value. This cut‐off was chosen to maintain balanced group sizes and ensure consistency with previous exploratory miRNA biomarker studies. To validate the robustness of this cut‐off, we performed sensitivity analyses using alternative cut‐off strategies: median expression value and ROC curve‐derived optimal cut‐off value. Survival curves were generated using the Kaplan–Meier method and compared using the log‐rank test. Independent prognostic factors were identified using the Cox proportional hazards regression model. Pearson's correlation analysis was employed. All statistical tests were two‐sided. In accordance with statistical principles, results were deemed statistically significant at the p < 0.05 level. Results The Expression Levels of miR‐941 and Its Diagnostic Performance in CRC Patients To elucidate the clinical significance of miR‐941 in CRC, its expression levels were initially assessed in serum. The relative amounts of miR‐941 in the serum from CRC patients were significantly increased in comparison to healthy controls (p < 0.001, Figure 1A). Furthermore, the relationship was assessed between miR‐941 expression and tumor malignant progression. Results indicated that miR‐941 expression levels were markedly elevated in patients with TNM stage III–IV in comparison to those with TNM stage I–II (Figure 1B, p < 0.001). Additionally, a higher level of miR‐941 expression was observed in patients who had undergone LNM compared to those without metastasis (Figure 1C, p < 0.001). The diagnostic value of miR‐941 for CRC was also evaluated. The area under the ROC curve (AUC) reached 0.882, with a 95% confidence interval (CI) of 0.845–0.919. The sensitivity was 76.00%, and the specificity was 85.33% (Figure 1D). Finally, we compared the diagnostic performance of miR‐941 with the established clinical biomarker CEA, which yielded an AUC of 0.787 (95% CI: 0.736–0.838) (Figure 1E). To evaluate whether miR‐941 added diagnostic value beyond CEA, combined ROC analysis was performed using binary logistic regression; the combined model (miR‐941 + CEA) achieved an AUC of 0.926 (95% CI: 0.897–0.955), with a sensitivity of 76.67% and specificity of 94.67% (Figure 1F), indicating that miR‐941 provides significant additive diagnostic value. These exploratory findings indicate that miR‐941 may serve as a potential complementary diagnostic biomarker for CRC, but external validation is needed. Expression and diagnostic value of miR‐941 in colorectal cancer (CRC). (A) Relative expression levels of miR‐941 in serum from healthy controls (n = 150) and CRC patients (n = 150). Data are presented as mean ± SD. (B) Relative expression levels of miR‐941 in CRC patients stratified by tumor node metastasis (TNM) stage. (C) Relative expression levels of miR‐941 in CRC patients stratified by lymph node metastasis (LNM) status. (D) Receiver operating characteristic (ROC) curve analysis of serum miR‐941 for discriminating CRC patients from healthy controls. (E) The diagnostic performance of carcinoembryonic antigen (CEA) was evaluated using ROC analysis in CRC patients. (F) Combined ROC curve analysis of miR‐941 and CEA using logistic regression, showing improved diagnostic performance. ***p < 0.001. To determine whether serum miR‐941 levels reflect tumor‐cell‐intrinsic expression, we analyzed miR‐941 expression in paired tumor and adjacent normal tissues from 30 randomly selected CRC patients. MiR‐941 expression was significantly higher in tumor tissues compared with adjacent normal tissues (p < 0.001, Figure S1A). Importantly, correlation analysis revealed a strong positive association between tissue miR‐941 levels and corresponding serum miR‐941 levels (r = 0.7826, p < 0.001, Figure S1B), demonstrating that serum miR‐941 levels closely reflect tumor miR‐941 expression. Association of miR‐941 Expression and Clinicopathological Parameters of CRC Patients To further investigate the implications of miR‐941 with clinical factors in CRC, patients were classified into two groups: low miR‐941 expression group and high miR‐941 expression group, based on the mean value of miR‐941. Significant correlations were observed between miR‐941 expression levels and both TNM staging and LNM status (Table 1). Specifically, among patients with TNM stages III–IV, the proportion expressing high miR‐941 expression was markedly higher than that in the low‐expression group (p = 0.008). Similarly, patients with LNM demonstrated significantly higher levels of miR‐941 expression compared to those without LNM (p = 0.005). However, miR‐941 expression levels showed no statistically significant association with patient age (p = 0.697), sex (p = 0.116), tumor location (p = 0.894), tumor size (p = 0.060), or differentiation grade (p = 0.099). TABLE 1The correlation of clinicopathological characteristics with miR‐941 in CRC patients.FactorsCases (n = 150)MiR‐941 expression p Low (n = 71)High (n = 79)Age (years)< 506831370.697≥ 50824042SexMale8545400.116Female652639Tumor locationColon9043470.894Rectal602832Tumor size (cm)< 58345380.060≥ 5672641TNM stageI–II7845330.008III–IV722646DifferentiationMedian‐high9148430.099Poor592336LNMNegative9252400.005Positive581939 Note: p < 0.05 indicates a significant difference.Abbreviations: CRC, colorectal cancer; LNM, lymph node metastasis; TNM, tumor note metastasis. The correlation of clinicopathological characteristics with miR‐941 in CRC patients. Note: p < 0.05 indicates a significant difference. Abbreviations: CRC, colorectal cancer; LNM, lymph node metastasis; TNM, tumor note metastasis. Prognostic Significance of miR‐941 in CRC Patients To evaluate the impact of miR‐941 expression on clinical outcomes in CRC patients, survival differences were analyzed among patients categorized by varying levels of miR‐941 expression using Kaplan–Meier survival analysis. Patients with high miR‐941 expression exhibited significantly poorer overall survival in comparison with those with low expression (log‐rank test, p < 0.001, Figure 2). Sensitivity analyses using median‐based and ROC‐mediated cut‐offs confirmed the same prognostic separation (log‐rank p < 0.001 for both, Figure S2A,B). Moreover, Cox proportional hazards regression analyses were conducted to identify independent prognostic factors. Univariate analysis revealed that miR‐941 overexpression (HR = 2.584, 95% CI = 1.498–4.457, p = 0.001), TNM stage (HR = 3.359, 95% CI = 1.930–5.844, p < 0.001), and LNM (HR = 3.473, 95% CI = 2.057–5.863, p < 0.001) were all significant risk indicators for overall survival (Figure 3A). Subsequently, age, tumor size, TNM stage, differentiation, LNM and miR‐941 expression were incorporated into the multivariate Cox regression analysis. After adjusting for these confounding factors, high miR‐941 expression remained an independent risk factor influencing overall survival in CRC patients (HR = 2.217, 95% CI = 1.276–3.852, p = 0.005, Figure 3B). Prognostic significance of miR‐941 expression in colorectal cancer (CRC) patients. Kaplan–Meier survival curves comparing overall survival between CRC patients with low miR‐941 expression and high miR‐941 expression using the mean expression value as the primary cut‐off. The log‐rank test was used to assess statistical significance (p < 0.001). Sensitivity analyses using median and ROC‐derived cut‐offs are shown in Figure S2. Cox regression analyses of factors associated with overall survival in patients with colorectal cancer (CRC). (A) Forest plot depicting the results of univariate Cox regression analysis for various clinicopathological variables and miR‐941 expression. (B) Forest plot displaying the results of multivariate Cox regression analysis, which incorporates age, tumor size, tumor node metastasis (TNM) stage, differentiation, lymph node metastasis (LNM), and miR‐941 expression. Hazard ratios (HRs) and 95% confidence intervals (CIs) are provided for each variable. Inhibition of miR‐941 Significantly Suppresses the Malignant Phenotypes of CRC Cells To explore the biological behaviors of miR‐941 in CRC, its expression levels were evaluated in CRC cell lines. MiR‐941 was found to be significantly overexpressed in CRC cell lines compared to normal human colorectal epithelial cells (NCM460) (p < 0.001, Figure 4A). Subsequently, loss‐of‐function experiments were conducted using the HCT116 and SW620 cell lines. MiR‐941 was effectively knocked down by transfecting specific inhibitors (p < 0.001, Figure 4B). In terms of cell proliferation, inhibition of miR‐941 significantly suppressed proliferative activity in HCT116 and SW620 cells compared to controls (Figure 4C,D). Furthermore, miR‐941 knockdown markedly reduced the number of cells migrating through the chamber, indicating a significant impairment in cell migration (p < 0.001, Figure 4E) and invasion capacity (p < 0.001, Figure 4F). These phenotypic changes are consistent with potential EMT regulation, although EMT markers were not directly assessed in the study. Regarding cell cycle analysis, miR‐941 inhibition caused HCT116 and SW620 cells to arrest in the G0/G1 phase, accompanied by a significant reduction in the proportion of S‐phase and G2/M‐phase cells (p < 0.001, Figure 4G,H). These changes were reversed by TRPS1 knockdown, indicating that TRPS1 mediates the cell cycle effects of miR‐941. Inhibition of miR‐941 suppresses malignant phenotypes and ferroptosis‐related genes in colorectal cancer (CRC) cells. (A) Relative expression of miR‐941 in normal human colorectal epithelial cells (NCM460) and CRC cell lines (HCT116, SW620, LoVo, SW480). (B) Relative expression of miR‐941 in HCT116 and SW620 cells after transfection with control, inhibitor‐NC, or miR‐941 inhibitor. (C, D) Cell proliferation was assessed by CCK‐8 assay in HCT116 (C) and SW620 (D) cells after miR‐941 inhibition at 24, 48, and 72 h. (E, F) Cell migration (E) and invasion (F) abilities were evaluated by Transwell assays in HCT116 and SW620 cells after miR‐941 inhibition. (G, H) Cell cycle distribution was analyzed by flow cytometry in HCT116 (G) and SW620 (H) cells after miR‐941 inhibition. (I–K) Levels of malondialdehyde (MDA, I) and glutathione (GSH, J), and reactive oxygen species (ROS, K) were measured in HCT116 and SW620 cells after miR‐941 inhibition. (L, M) Western blot analysis of GPX4 and SLC7A11 protein expression in HCT116 and SW620 cells after miR‐941 inhibition. Data are presented as mean ± SD from three independent experiments. ***p < 0.001. Furthermore, key indicators associated with ferroptosis were examined. Changes consistent with ferroptosis were observed. In miR‐941‐knockdown cells, MDA was significantly augmented (p < 0.001, Figure 4I), while the level of GSH markedly decreased (p < 0.001, Figure 4J). To directly assess ferroptosis, lipid ROS accumulation was measured. MiR‐941 inhibition significantly increased lipid ROS levels in both HCT116 and SW620 cells (p < 0.001, Figure 4K). Western blot analysis revealed that miR‐941 knockdown led to downregulation of the key ferroptosis regulators GPX4 and SLC7A11 at the protein level (p < 0.001, Figure 4L,M). Collectively, these findings indicate that miR‐941 inhibition induces changes consistent with ferroptosis; definitive confirmation would require rescue experiments with specific ferroptosis inhibitors. TRPS1 Is Identified as a Direct Functional Target of miR‐941 To elucidate the molecular mechanism of miR‐941 in CRC, its downstream target genes were explored. Multiple potential target genes of miR‐941 were predicted through bioinformatics analysis (Figure 5A). Among these candidates, TRPS1 exhibited the lowest expression levels in the HCT116 and SW620 cell lines (Figure 5B), warranting further investigation. A conserved binding site was identified in the 3′‐UTR of TRPS1 that corresponds to the seed sequence of miR‐941 (Figure 5C). Luciferase activity in the wild‐type reporter plasmid was significantly suppressed in cells co‐transfected with the miR‐941 mimic. This inhibition was completely reversed upon mutation of the binding site (Figure 5D). Subsequently, the expression patterns of TRPS1 were examined in clinical CRC samples and cell lines. Compared to healthy controls, TRPS1 mRNA expression in serum was significantly downregulated in CRC patients (p < 0.001, Figure 5E). A significant negative correlation between miR‐941 and TRPS1 was observed in CRC (r = −0.7218, p < 0.001, Figure 5F). However, as serum TRPS1 mRNA may originate from multiple sources including blood cells, immune cells, platelets, and extracellular vesicles, this exploratory finding does not directly demonstrate a tumor‐cell‐intrinsic miR‐941‐TRPS1 regulatory relationship. To directly address this, we examined TRPS1 expression in paired tumor and adjacent normal tissues from 30 CRC patients. TRPS1 expression was significantly lower in tumor tissues compared with adjacent normal tissues (p < 0.001, Figure S3A). Importantly, within tumor tissues, miR‐941 expression showed a significant negative correlation with TRPS1 expression (r = −0.5373, p < 0.001, Figure S3B). Similarly, TRPS1 expression was consistently lower in several CRC cell lines (HCT116, SW620, LoVo, SW480) compared to normal human colorectal epithelial cells (NCM460) (p < 0.001, Figure 5G). More importantly, miR‐941 was knocked down in HCT116 and SW620 cells to verify its regulatory role on TRPS1. Following miR‐941 inhibition, TRPS1 expression was significantly increased in CRC cells (p < 0.001, Figure 5H). TRPS1 is identified as a direct target of miR‐941. (A) A venn diagram was constructed using three datasets: TargetScan, TargetBase, ENCORI, resulting in the identification of eight candidate genes. (B) Validation of candidate target gene expression in NCM460, HCT116, and SW620 cells. TRPS1 showed the most significant downregulation in CRC cells. (C) A schematic representation of the wild‐type (TRPS1‐WT) and mutant (TRPS1‐MUT) luciferase reporter constructs, and the predicted binding site between miR‐941 and the TRPS1 3′UTR. (D) Luciferase activity in HCT116 and SW620 cells co‐transfected with TRPS1‐WT or TRPS1‐MUT reporter plasmid and miR‐941 mimic, inhibitor, or their corresponding controls. (E) Relative expression of TRPS1 mRNA in serum from healthy controls and CRC patients. (F) Correlation analysis between miR‐941 and TRPS1 mRNA expression levels in CRC. (G) Relative expression of TRPS1 mRNA in NCM460 and CRC cell lines (HCT116, SW620, LoVo, SW480). (H) Relative expression of TRPS1 mRNA in HCT116 and SW620 cells after transfection with control, inhibitor‐NC, or miR‐941 inhibitor. (I) TRPS1 protein expression in HCT116 and SW620 cells was assessed post‐transfection with control, inhibitor‐NC, or miR‐941 inhibitor. Data are presented as mean ± SD. ***p < 0.001. To further confirm this regulatory relationship at the protein level, Western blot analysis was conducted in HCT116 and SW620 cells post‐miR‐941 inhibition. As illustrated in Figure 5I, TRPS1 protein expression was markedly upregulated in miR‐941 inhibitor‐transfected cells compared to the inhibitor‐NC controls (p < 0.001), which is consistent with the mRNA data. MiR‐941 Mediates Cellular Malignant Phenotypes and Ferroptosis‐Related Changes of CRC Cells by Targeting TRPS1 To confirm that TRPS1 is a key downstream effector mediating the oncogenic function of miR‐941, rescue experiments were conducted in HCT116 and SW620 cells. qRT‐PCR validated effective knockdown of TRPS1 across four experimental groups: NC‐inhibitor + si‐NC, NC‐inhibitor + si‐TRPS1, miR‐941 inhibitor + si‐NC, and miR‐941 inhibitor + si‐TRPS1 (p < 0.001, Figure 6A). Rescue experiments confirm that miR‐941 enhances CRC progression by targeting TRPS1. (A) Relative expression of TRPS1 mRNA in HCT116 and SW620 cells across four experimental groups. (B, C) Cell proliferation assessed using CCK‐8 assay in HCT116 (B) and SW620 (C) cells across the four experimental groups. (D, E) Cell migration (D) and invasion (E) abilities evaluated using Transwell assays in HCT116 and SW620 cells across the four experimental groups. (F, G) Cell cycle distribution analyzed by flow cytometry in HCT116 (F) and SW620 (G) cells across the four experimental groups. (H, I) Levels of malondialdehyde (MDA, H) and glutathione (GSH, I) in HCT116 and SW620 cells across the four experimental groups. J. Relative lipid reactive oxygen species (ROS) levels were measured across four experimental groups. (K, L) Glutathione peroxidase 4 (GPX4) and Solute carrier family 7 member 11 (SLC7A11) protein expressions were determined via Western blot analysis. Representative Western blot images were presented. Data are presented as mean ± SD. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001. MiR‐941 knockdown significantly inhibited proliferation in HCT116 and SW620 cells. However, in the rescue experiments, where both miR‐941 and TRPS1 were simultaneously knocked down, the suppressed proliferation capacity was markedly restored (p < 0.001, Figure 6B,C). MiR‐941 inhibition significantly reduced cell migration and invasion capabilities. Nevertheless, when its target gene TRPS1 was concurrently knocked down, cell migration and invasion capabilities exhibited a marked rebound compared to the miR‐941‐only knockdown group (p < 0.001, Figure 6D,E). Additionally, miR‐941 knockdown led to G0/G1 phase cell cycle arrest. In the rescue experiments, simultaneous knockdown of TRPS1 partially alleviated this cell cycle arrest, facilitating a greater number of cells entering the S phase for DNA replication (p < 0.001, Figure 6F,G). In ferroptosis‐related assays, miR‐941 inhibition significantly elevated MDA levels and depleted intracellular GSH levels. Notably, with concurrent TRPS1 knockdown, MDA accumulation was markedly suppressed, and GSH depletion was alleviated (p < 0.001, Figure 6H,I). To further confirm the role of TRPS1 in miR‐941‐mediated ferroptosis‐related regulation, lipid ROS levels, GPX4 and SLC7A11 protein expression were examined. As shown in Figure 6J, the increase in lipid ROS induced by miR‐941 inhibition was significantly attenuated upon TRPS1 knockdown (p < 0.05). Consistently, miR‐941 inhibition significantly downregulated GPX4 and SLC7A11 expression, which was reversed by TRPS1 knockdown (p < 0.05, Figure 6K,L). These results suggested that TRPS1 mediates the ferroptosis‐related changes induced by miR‐941 inhibition. Discussion The present findings provide the first comprehensive demonstration of an oncogenic role of miR‐941 in CRC, integrating clinical validation with mechanistic exploration. Our findings show that miR‐941 is significantly increased in the serum of CRC patients and cell lines. Notably, our observation of miR‐941 upregulation in CRC aligns with previous findings by Gungormez et al., who identified miR‐941 as an obviously upregulated miRNA in stage IIIA colon cancer tissue specimens using microarray analysis [28]. Clinically, this elevated expression is preliminarily associated with advanced TNM stage and LNM, and serves as an independent indicator of inferior overall survival in this single‐center cohort. Furthermore, the diagnostic performance highlights its potential as a new non‐invasive indicator for CRC, which is consistent with articles in other tumors, such as laryngeal squamous cell carcinoma [20]. Notably, miR‐941 demonstrated diagnostic performance comparable to the established biomarker CEA, suggesting that miR‐941 may serve as a complementary biomarker in clinical practice. However, these findings are exploratory and require validation in independent external cohorts. To elucidate the functional role of miR‐941, knockdown of miR‐941 was conducted in CRC cell lines. It was demonstrated that inhibiting miR‐941 suppressed malignant phenotypes, including cell proliferation, migration, and invasion. These tumor‐promoting functions of miR‐941 are conserved in several tumors, such as breast cancer [19] and lung adenocarcinoma [18]. Furthermore, miR‐941 knockdown induced G0/G1 phase cell cycle arrest and triggered ferroptosis‐related changes. A comprehensive validation of ferroptosis‐related genes through detection of GPX4 and SLC7A11 downregulation, accumulation of lipid ROS, and genetic rescue experiments demonstrating TRPS1 dependence. These data collectively support that miR‐941 is associated with ferroptosis suppression in CRC. It is acknowledged that ferroptosis is one of the mechanisms involved and that other forms of cell death may also contribute to the observed phenotypes. Ferroptosis, an iron‐dependent form of regulated cell death, has emerged as a crucial tumor suppression mechanism [29, 30, 31]. Interestingly, the cell cycle regulatory role of miR‐941 has been observed in breast cancer, where it alters histone H3 Ser10 phosphorylation and regulates p21 and Cyclin D1 expression [19]. Our findings indicate that miR‐941's oncogenic action may involve protecting CRC cells from cell death, presenting a new dimension to its function. The mechanistic investigation identified TRPS1 as a direct target gene of miR‐941. This interaction was confirmed through bioinformatics analysis and luciferase reporter assays, and validation at both mRNA and protein levels in CRC cell lines. In clinical samples, we observed a negative correlation between serum miR‐941 and TRPS1 mRNA; however, this finding is exploratory and requires tissue‐based validation. Moreover, a significant negative correlation was observed between miR‐941 and TRPS1 expression in clinical samples. By knocking down TRPS1 with miR‐941 inhibition, the anti‐tumor effects elicited by miR‐941 knockdown were reversed across the examined phenotypes, including proliferation, migration, invasion, cell cycle progression, and ferroptosis‐related changes. This reversal establishes that the oncogenic effects of miR‐941 are mediated primarily through the suppression of TRPS1. The tumor‐suppressive role of TRPS1 identified in our study aligns with previous findings in colon cancer. Huang et al. reported that TRPS1 is down‐regulated in highly metastatic colon cells [32]. The regulatory relationship we identified, wherein miR‐941 promotes CRC progression by inhibiting TRPS1, further substantiates this tumor‐suppressive role and offers a plausible mechanism for its downregulation in cancer. However, our data seem to contradict earlier findings in colon cancer. While Zhang et al. reported that TRPS1 is upregulated in colon cancer and associated with poor prognosis [33], our data indicate that TRPS1 functions as a tumor suppressor in CRC. This discrepancy may be attributed to several factors, including variations in experimental systems, cancer subtypes, or distinct molecular contexts. As a transcription factor, TRPS1 may exert its tumor‐suppressive effects through multiple downstream pathways. First, TRPS1 may regulate epithelial‐mesenchymal transition (EMT) phenotypes through FOXA1. Huang et al. demonstrated that TRPS1 activates FOXA1 transcription, which in turn suppresses mesenchymal markers such as Vimentin and Snail [32]. Therefore, it is plausible that miR‐941 affects CRC cell migration and invasion by regulating TRPS1 and EMT. However, we did not directly measure EMT markers in this study. Consequently, the involvement of EMT in the miR‐941/TRPS1 axis remains a hypothesis based on prior literature rather than a conclusion directly demonstrated by our data. Second, TRPS1 may regulate cell cycle progression. TRPS1 has been shown to interact with PSAT1 and modulate Cyclin D1 expression [34]. The G0/G1 phase arrest observed upon miR‐941 inhibition aligns with the possibility that TRPS1 upregulation suppresses Cyclin D1 activity. However, we did not assess Cyclin D1 in this study. Consequently, the involvement of these molecules in the miR‐941/TRPS1‐mediated cell cycle phenotypes remains speculative and requires future investigation. While previous studies have reported context‐dependent roles of TRPS1 in CRC, our study provides the first evidence that TRPS1 is directly targeted by miR‐941 and is associated with ferroptosis‐related pathogenesis in CRC cells, thereby suggesting a potential regulatory axis in CRC pathogenesis. This discovery extends the known functions of TRPS1 beyond EMT and cell cycle regulation to include a possible role in ferroptosis, and identifies miR‐941 as a candidate upstream regulator of this tumor‐suppressive pathway. However, the precise molecular mechanism by which TRPS1 regulates ferroptosis requires further investigation. The oncogenic nature of miR‐941 across various tumors suggests that it may regulate fundamental cancer hallmarks through tissue‐specific mechanisms. While we identified TRPS1 as its key target in CRC, other studies have identified different targets in other tumors, such as FOXN4 in lung adenocarcinoma [18] and histone modification regulators in breast cancer [19]. This pattern of tissue‐specific targeting underscores the complexity of miRNA‐mediated gene regulation in cancer and highlights the necessity of conducting specific mechanistic studies. In spite of these significant findings, our study has several limitations. Firstly, the clinical conclusions are drawn from a single‐center retrospective cohort without independent validation. Therefore, the reported diagnostic and prognostic performance of serum miR‐941 should be considered exploratory rather than clinically validated. Additionally, we did not include patients with benign colorectal diseases or other gastrointestinal malignancies. Consequently, the specificity of miR‐941 for CRC versus colorectal conditions remains unknown. Future multi‐center studies with larger and more diverse populations are needed to confirm the diagnostic and prognostic value of miR‐941 in clinical practice. Additionally, although RNU6B stable Ct values in our cohort support its use as a reference gene, the lack of a spike‐in control is a limitation. Serum miR‐941 was measured only from preoperative samples, and postoperative changes in miR‐941 levels were not assessed. Therefore, whether miR‐941 levels change after tumor resection or correlate with treatment response remains unknown. Secondly, while we established TRPS1 as a key downstream effector, the molecular pathways through which TRPS1 executes its tumor‐suppressive functions in CRC remain to be elucidated. While our serum TRPS1 mRNA data are exploratory, we have provided tissue‐based validation in 30 paired tumor samples. The results support the tumor‐cell‐intrinsic miR‐941/TRPS1 regulatory relationship. We did not perform immunohistochemistry for TRPS1 protein in tumor specimens, which remains a goal for future studies. Thirdly, the absence of in vivo validation limits the translational interpretation of our findings. Our in vitro data suggest an association between the miR‐941/TRPS1 axis and ferroptosis‐related phenotypes, but confirmation in animal models is needed. Finally, while we observed changes consistent with ferroptosis, we did not perform rescue experiments with ferroptosis‐specific inhibitors, nor did we determine whether TRPS1 directly regulates ferroptosis‐related genes. Therefore, our findings should be interpreted as establishing an association rather than a definitive regulatory mechanism. Future studies incorporating inhibitor rescue and chromatin immunoprecipitation (ChIP) assays are needed to further elucidate the precise role of this axis. Despite these limitations, our findings carry significant implications. Clinically, serum miR‐941 shows promise as a valuable diagnostic and prognostic biomarker. From a therapeutic perspective, the miR‐941/TRPS1 axis represents a novel potential target for molecular therapy. Strategies aimed at inhibiting miR‐941 may reactivate TRPS1 expression, suppress tumor growth, and sensitize cells to ferroptosis‐related pathogenesis. This approach offers a promising new avenue for treating CRC. In conclusion, our study establishes miR‐941 as a potential prognostic biomarker and a key oncogenic driver in CRC. These findings are exploratory and require external validation. By identifying the miR‐941/TRPS1 axis and its association with ferroptosis‐related phenotypes, these insights deepen our understanding of CRC pathogenesis and highlight the miR‐941/TRPS1 axis as a candidate target for diagnostic and therapeutic strategies. Author Contributions Yang Liu: software, formal analysis, data curation, visualization, conceptualization, writing – original draft. Hong Li: conceptualization, methodology, validation, visualization, writing – original draft, software, data curation, formal analysis. Jialin Li: methodology, writing – review and editing, project administration, software, supervision, investigation. Hua Chen: project administration, methodology, supervision, investigation, writing – original draft. Xinchun Li: writing – review and editing, methodology, investigation, software, project administration. Yanmin Chen: writing – review and editing, methodology, formal analysis, data curation, supervision, conceptualization. Funding This study was funded by 2025 Changde Municipal Science and Technology Innovation Guiding Program Projects (No. 2025ZD270). Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Correlation between serum and tissue miR‐941 expression in CRC patients (n = 30). (A) Relative expression of miR‐941 in paired adjacent normal and tumor tissues. Data are presented as mean ± SD. ***p < 0.001. (B) Correlation analysis between serum miR‐941 levels and corresponding tumor tissue miR‐941 levels (r = 0.7826, p < 0.001). Figure S2: Sensitivity analyses of the prognostic value of miR‐941 using alternative cut‐off strategies. Kaplan–Meier survival curves comparing overall survival between CRC patients with low and high miR‐941 expression using (A) median expression value as the cut‐off, and (B) ROC‐derived optimal cut‐off based on the Youden index. High miR‐941 expression was significantly associated with poorer overall survival (log‐rank test, p < 0.001 for both). Figure S3: TRPS1 expression and its correlation with miR‐941 in CRC tissues (n = 30). (A) Relative expression of TRPS1 mRNA in paired adjacent normal and tumor tissues. Data are presented as mean ± SD. ***p < 0.001. (B) correlation analysis between miR‐941 and TRPS1 expression levels in tumor tissues (r = −0.5373, p < 0.001).